Modulation of MDL-1 activity for treatment of inflammatory disease
AssigneeBayer Schering Pharma Aktiengesellschaft
InventorsDaryl Faulds, Stefano Fiorucci, Ying-Ping Jiang, Yi Liu, John Parkinson
Life of this patent
Estimating the term…
Abstract
The present invention provides compositions and methods that modulate MDL-1 activity in a cell, in vivo or in vitro. In particular, the present invention provides methods for treatment of inflammatory diseases using synthetic or recombinant compositions that modulate MDL-1 activity in a mammalian cell, in vivo or in vitro. More particularly, the present invention provides protein compositions useful for the treatment of diseases having an inflammatory process mediated by MDL-1.
Claims40
An MDL-1 fusion protein that modulates an MDL-1 activity in a mammalian cell, in vivo or in vitro.
Dependencies are inferred from the claim text.